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ABSTRACT 26 
 27 
Background 28 
Non-muscle-invasive bladder cancer (NMIBC) causes a considerable health burden due to 29 
the high recurrence and progression rates. Past studies have identified multiple candidate loci 30 
associated with NMIBC prognosis, albeit lacking validation. Moreover, scarce reports exist 31 
on genetic susceptibility to independent prognostic predictors of NMIBC, such as stage or 32 
grade.  33 
Objective 34 
To investigate genetic associations with NMIBC tumour and patient characteristics at the 35 
time of diagnosis. 36 
Design, Setting, and Participants 37 
A sample of 653 NMIBC cases come from the Bladder Cancer Prognosis Programme 38 
(BCPP). Replication of the significant findings was conducted in the Nijmegen Bladder 39 
Cancer Study (NBCS) cohort (N=1470).  40 
Outcome Measurements and Statistical Analysis 41 
Genome-wide association study (GWAS) was carried out for outcomes of tumour size (as 42 
continuous variable in centimetres), stage (Tis and T1 vs Ta), grade (G3 vs G2 and G1), and 43 
age (as continuous (years) and dichotomous (70.2 years as a cut-off) variables). 44 
Results and Limitations 45 
Significant (P<5E-08) associations (N=61) with tumour size, stage, grade, and age were 46 
identified in the GWAS discovery stage. None of the variants were independently 47 
significantly associated in the replication cohort. A meta-analysis of both cohorts suggests 48 
rs180940944 (13q13.3 locus, NBEA) was associated with tumour size as a continuous 49 
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variable (ß=0.9 cm, p=2.92E-09). However, other SNPs in this region did not show evidence 50 
of association in the meta-analysis.  51 
Conclusions 52 
Our study suggests rs180940944 (NBEA) is associated with an increased NMIBC tumour size 53 
at the time of diagnosis. Given study limitations, further replication is essential to validate the 54 
finding.   55 
Patient Summary 56 
Current study reports on a genome-wide association study on non-muscle-invasive bladder 57 
cancer tumour and patient characteristics. We suggest NBEA gene might be associated with 58 
increased tumour size at the time of diagnosis. The result must be replicated to establish 59 
validity.  60 
 61 
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INTRODUCTION 75 
Urinary bladder cancer (UBC) accounts for 430 000 new cases worldwide annually, with 70-76 
80% of new cases presenting as non-muscle-invasive bladder cancer (NMIBC) [1]. NMIBC 77 
causes significant burden on healthcare systems due to high recurrence and progression rates 78 
(5-year recurrence rate: 50-70%, 5-year progression rate: 10-30%) [1]. Considerable clinical 79 
improvements could be made by better, even personalised, prognostication and risk 80 
stratification [1]. There have been several attempts to apply different approaches for accurate 81 
disease prognostication, and although descriptive on a population-level, a substantial lack of 82 
precision of individual outcomes remains [2], requiring ongoing improvement. 83 
Few candidate-gene studies of UBC prognosis exist, with limited successful replication [3-5].  84 
A recent study reported that out of 114 reported loci for UBC progression and prognosis, 85 
only six single nucleotide polymorphisms (SNPs) showed significant associations in an 86 
independent cohort, namely: NMIBC progression (rs6678136 (RGS4), rs11585883 (RGS5)), 87 
recurrence among Bacillus Calmette–Guérin (BCG)-treated NMIBC patients (rs1799793 88 
(ERCC2), rs187238 (IL18)), and muscle-invasive bladder cancer (MIBC) overall survival 89 
(rs12035879 (RGS5), rs2075786 (TERT)) [3]. Powerful GWAS studies on NMIBC 90 
prognosis show promise, but are still ongoing [6]. 91 
A previous attempt to include genetic variation failed to increase prognostic tool performance 92 
[7], suggesting the issue is more complex. However, latter study utilised a relatively small 93 
panel of SNPs (170,000), which has lower power of discovering significant loci in 94 
comparison to genotype-imputed sets harbouring millions of variants for analysis [8]. The 95 
inter-study lack of consensus might be due to several reasons: spurious findings, lack of 96 
statistical power, and variation in outcome definition.  97 
Other studies also suggest significant genetic signals might be only present for tumours of 98 
certain grade or stage [9, 10]. However, reports on genetic associations for characteristics that 99 
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directly influence NMIBC outcome are scarce, precluding further investigations on their 100 
relevance for NMIBC prognostication.  101 
To provide more evidence on potential genetic associations, we have performed a GWAS on 102 
key NMIBC characteristics (stage, grade, size of the tumour, EORTC risk category), as well 103 
as age at the time of diagnosis within the West Midlands’ Bladder Cancer Prognosis 104 
Programme (BCPP) cohort including replication in the Nijmegen Bladder Cancer Study 105 
(NBCS).  106 
 107 
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MATERIAL AND METHODS 125 
Participants and genotyping 126 
BCPP is a prospective cohort that initially recruited 1,544 eligible patients and is described in 127 
more detail elsewhere [11]. Clinical data on stage, grade, and size of tumours and 128 
demographic information (age, gender) were gathered with bespoke case report forms. 129 
Tumour size of the largest tumour was established visually while performing cystoscopy. 130 
Blood samples of 888 participants with confirmed UBC were genotyped on the Illumina 131 
Infinium OmniExpress-24 BeadChip array at deCODE Genetics (Iceland).  132 
Tumours of stages pTa, pT1, or pTis were included to limit our analyses to NMIBC, resulting 133 
in a dataset of 712 cases. 134 
Quality control (QC)  135 
QC procedures were carried out using PLINK v1.90 [12]. The exact thresholds applied and 136 
number of exclusions per step are outlined in Figure 1.  137 
Generic QC procedures per individual excluded those with an inconclusive gender call, 138 
excessive genotype missingness rate, increased or reduced genotype heterozygosity rate, 139 
duplicate samples, and related individuals. 140 
To avoid any bias introduced by population stratification, a principal component analysis 141 
(PCA) was carried out. Investigation of PCA plots resulted in exclusion of clear population 142 
outliers. Genomic inflation factor (λ) value was estimated for all outcomes of interest; none 143 
of the values exceeded 1.03.  144 
Marker-specific QC procedures covered excluding SNPs deviating from the Hardy-Weinberg 145 
equilibrium, exceeding acceptable missing rate, and rare variants.  146 
In total, a dataset consisting of 653 individuals and 597,764 markers remained for further 147 
analyses. 148 
Imputation 149 
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Imputation utilised a two-step approach: haplotype phasing by Eagle v2.3.2 [13], followed by 150 
genotype imputation with IMPUTE2 [14], using 1000 Genomes Phase 3 [15] as a reference 151 
panel in the genome build 19 (GRCh37/hg19). Once imputed, the dataset was filtered for 152 
SNPs with info values (an imputation accuracy measure) of >0.3 and MAFs of >1%, 153 
resulting in a dataset containing 11,914,228 markers available for genetic association 154 
analyses.   155 
Statistical analysis 156 
Statistical analyses were performed using SNPtest v2.5.2 [8] and R statistical package 157 
(v3.3.2) [16]. 158 
To establish the relation between germline variation and tested outcomes, linear regression 159 
was used for continuous variables and logistic regression for all binary endpoints. Age was 160 
tested as a continuous (years) and binary variable (mean was considered as a cut-off value for 161 
categorisation (resulting in strata of </≥ 70 years)). Tumour size (cm) was tested as a 162 
continuous and categorical variable (</≥ 3cm [17]). Stage (Tis and T1 versus Ta) and grade 163 
(G3 versus G2 and G1) were treated as binary variables. In addition, low-, intermediate-, and 164 
high-risk EORTC categories were assigned to each NMIBC case and were tested as a 165 
dichotomous variable of high- versus low- and intermediate-risk groups [17].  166 
All analyses were adjusted for participant gender and first five genetic principal components 167 
to increase estimate precision and to adjust for any potential residual population stratification 168 
bias. An association was held significant if p-value <5E-08, and promising if below 5E-06. 169 
Post-GWAS power calculations were carried out in web-based GAS Power Calculator [18].  170 
Manhattan and QQ graphs were plotted for each tested outcome. For significant hits, regional 171 
association plots were constructed using LocusZOOM tool [19], except for hits that have not 172 
yet been assigned an ID (rsID). 173 
Functional annotation  174 
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Identified significant SNPs were mapped using a web-based SNPnexus tool [20], with 175 
Ensembl [21] (Version 74) as a functional annotation system.  176 
Replication 177 
Genome-wide significant hits were attempted to replicate in a sample of 1470 NMIBC cases 178 
from the NBCS [22] (Figure 1). Briefly, the NBCS recruited UBC patients via the 179 
population-based cancer registry in the Nijmegen region. Eligible cases were diagnosed 180 
during 1995-2006 and were under the age of 75; additional data was collected via linkage 181 
with hospital-patient records [22], including tumour size, which was reported after visual 182 
evaluation during cystoscopy. Details of genotype data cleaning and initial analysis is 183 
provided in detail elsewhere [22].  184 
We used META [23] software to perform meta-analysis on association results of both 185 
cohorts and calculated a combined p-value per SNP. An inverse-variance method was used, 186 
assuming a random-effects model. I2 index and p-value were calculated to evaluate potential 187 
heterogeneity between the estimates of the two cohorts [23].  188 
 189 
 190 
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RESULTS 200 
Baseline clinical characteristics of the discovery and replication cohorts are shown in Table 201 
1. 202 
 Majority of cases in BCPP were male (78.1%), with an average age of 70 years. Tumour size 203 
mean was 2.5 cm, and most of the participants were diagnosed with stage Ta (68%) and T1 204 
(30.5%) tumours. More than a third of cases presented as G2 (37.5%), followed by G3 205 
(31.7%) and G1 (29.2%) NMIBC. The distribution of variable categories and measures were 206 
similar between the BCPP and NBCS cohorts.  207 
In the discovery-stage analysis, a total of 61 SNPs, corresponding to 29 different regions, 208 
showed genome-wide statistically significant associations with at least one of the outcomes. 209 
Out of those, 20 loci were mapped to genes (all intronic regions) (Table 2). Significant 210 
associations were observed for size and age as continuous variables, as well as for binary 211 
outcomes of stage, grade, and age. 212 
Most of the SNPs (N=47) were found to be associated with tumour size, the effect sizes 213 
ranging from 0.65 (rs35225990 in FAM194B, p= 2.85E-08) to 2.6 (rs370572716 in 9p13.1, 214 
p=4.04E-09) centimetres (Table 2).  215 
One SNP in 9q22.32, rs142492877, showed statistically significant association with 216 
decreased age at diagnosis of almost one year (ß=-0.95, SE=0.16, p=1.05E-08). Age as a 217 
binary trait showed associations in the same direction, although in a different genomic region 218 
(7q31.33) with an odds ratio (OR) ranging between 2.46 (rs17149580, p=2.18E-08) and 2.51 219 
(rs17149636, p=1.62E-08) across eight SNPs.  220 
The 14q11.2 locus showed strong associations with being diagnosed with a higher grade of 221 
NMIBC (rs15091489 in the TRAV16 gene (OR=3.42, 95%CI: 2.11-5.55, p=5.13E-09) and 222 
rs116923391 (OR=3.86, 95% CI: 2.38-6.26, p=2.07E-10)). 223 
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Several protective variants for tumour stage were observed, namely: rs117248430 in ANKS6 224 
(OR=0.003, 95%CI=1.71E-09-3895.6, p=3.73E-08), and two markers in the SLCO1B1 gene 225 
(rs76497895 (OR=0.03, 95%CI=0.001-0.83, p=4.18E-08); rs116946525 (OR=0.03, 226 
95%CI=0.001-0.83, p=4.23E-08)). The strength of the effect and corresponding confidence 227 
intervals in ANKS6 might be explained by a very low MAF (<0.01%) among cases. 228 
A Manhattan plot for tumour size as a continuous outcome (Figure 2) also shows there are 229 
several polymorphisms in linkage disequilibrium (LD) with the leading SNP (Manhattan 230 
plots for all other tested outcomes are available in the Supplementary Figures 1-6). 231 
Regional association plot of 13q13.3 (Figure 3) in the BCPP confirms high LD with 232 
surrounding variants, all mapping to the NBEA gene (although they did not reach the 233 
statistical significance). Regional association plots for the remaining SNPs identified in the 234 
discovery stage are presented in Supplementary Figures 7-33.  235 
In the replication stage, 50 out of 61 SNPs were available to test in NBCS (Table 2).  None 236 
of these SNPs were significantly associated with the same outcomes in NBCS. A meta-237 
analysis of both cohorts showed variant rs180940944 in 13q13.3 locus to be associated with 238 
increased tumour size at diagnosis (ß=0.96, SE=0.16, p=2.92E-09), although the effect is 239 
likely driven by BCPP data. Nevertheless, low I2 estimate (I2=0%, p(heterogeneity)=0.75) 240 
indicated there was no significant heterogeneity between the two cohorts for the replicated 241 
SNP. A conditional association analysis on rs180940944 showed the associations in the 242 
NBEA gene are likely to be driven by the top SNP, as none of the variants have reached 243 
genome-wide significance when controlled for the effect of rs180940944 (Supplementary 244 
Figure 34). Nevertheless, the analysis also suggests there is a region in the NBEA gene of 245 
mildly inflated p-values, independent of the rs180940944. 246 
 247 
 248 
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DISCUSSION 249 
We have investigated genetic associations with NMIBC tumour (size, stage, grade) and 250 
patient (age, EORTC risk category) characteristics at the time of diagnosis within the BCPP 251 
cohort.  252 
Multiple loci were identified in the discovery stage that are novel in the context of NMIBC. 253 
One SNP, rs180940944, has reached statistical significance in a meta-analysis of two 254 
NMIBC cohorts, mapping to the intronic region of the NBEA gene on 13q13.3. However, 255 
associations of other SNPs in the NBEA have failed to be reproduced.  256 
NBEA proteins have been mostly observed to play a significant role in synapse development 257 
and function [24]. NBEA dysregulation does not affect the establishment of synapses per se, 258 
but rather their intra-cellular organisation [24]. An in-depth analysis revealed impaired 259 
synaptic ability was mostly due to the inappropriate distribution of actin, a protein essential 260 
for synapse cytoskeleton structure [24]. The effect is most likely present due to alterations in 261 
the Golgi-dependent processes of inter- and intra-cellular compound trafficking, including 262 
actin and neural receptors [24].  263 
The synaptic alterations are likely to be the contributing cause of autism spectrum disorders 264 
[24]; however, the Golgi-related pathway may have a wider phenotypic manifestation [25], 265 
including cancer. The prognostic utility of NBEA has been investigated in gastric cancer [26] 266 
and oropharyngeal squamous cell carcinomas (OPSCC) [27], with promising results. 267 
Collectively, these observations implicate the pleiotropic nature of NBEA effect across a 268 
variety of traits. 269 
In our study, we suggest there is an association between NBEA and increased NMIBC tumour 270 
size. The role of Golgi complex in cancer progression has been reported independently, and 271 
disruptions in normal protein transportation can contribute to increased tumour size and, 272 
eventually, progression [25].  273 
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Our findings should be interpreted cautiously. Substantial sample sizes of specific 274 
phenotypes such as ours are rare, and suffer from limited power to capture true genetic 275 
associations, and spurious associations due to random effects cannot be ruled out. Our post-276 
hoc power calculations [18], underscore the importance of current analysis being ran on 277 
bigger cohorts (e.g. association rs150914897 (14q11.2) of an OR=3.42 had power of 79%, 278 
but it drops to only 16% for an OR=2.5, hence we may have missed existing associations of 279 
more modest effect size).   280 
Furthermore, tumour size measurements are subject to variability, degree of which is difficult 281 
to establish. The lack of any genome-wide significant associations for categorised tumour 282 
size (</≥ 3 cm [17]) adds substantial caution in consideration of our main findings and study 283 
power. However, clinically-relevant tumour size categories may not be adequate in a genetic 284 
context, and different categorisation may be used in future analyses.  285 
Our study only focused on NMIBC instead of a merged group of UBC, and we are unable to 286 
comment on whether these genetic loci are relevant for advanced UBC. Given considered 287 
limitations, we see this study as true to the GWAS design of hypothesis-generating nature, 288 
instead of one offering conclusive findings. Hence, further replication is of essence to 289 
establish validity of described results.  290 
The 13q13.3 locus has not been observed in prior studies on NMIBC. It might be due to us 291 
using an independent prognostic marker of NMIBC (i.e. tumour size) instead of recurrence 292 
and/or progression as an outcome. Larger tumour indicates a worse disease course [17], but 293 
there are other components that contribute to NMIBC prognosis. In a clinical setting, each 294 
tumour characteristic (e.g. size) carries a different weighting [17], collectively contributing to 295 
an endpoint (e.g. recurrence).  296 
Importantly, powerful studies on UBC risk have already shown some signals to only be 297 
associated with MIBC (UBC of T2-T4) [10]. Furthermore, a genome-wide methylation 298 
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investigation on high-grade NMIBC cases revealed epigenetic changes different from their 299 
low-grade counterparts [9]. Direct comparability of these reports is limited, but we see the 300 
unravelling genetic complexity within UBC being a connecting thread between all studies. 301 
We therefore believe it is likely separate genetic relationships are present for NMIBC 302 
determinants, rather than overall prognostic outcomes.  303 
 304 
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 309 
 310 
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 312 
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CONCLUSIONS 324 
Our study suggests variations in 13q13.3 locus may contribute to an increased NMIBC 325 
tumour size in a European population. Further studies are warranted to confirm the 326 
association.  327 
 328 
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